Our dermal absorption studies help pharmaceutical manufacturers evaluate skin absorption of topical drug delivery systems and over-the-counter pharmaceutical products, and provide agrochemical, chemical and cosmetic manufacturers with product risk assessment data following skin exposure.

We offer testing outlined in OECD 427 (in vivo studies in rodent models) and OECD 428 (in vitro studies using human and animal skin), which are often performed in parallel to predict dermal absorption in humans (sometimes called “the triple pack” or “parallelogram” approach).

Our scientists employ a variety of custom-made diffusion cells that can be used for dermal absorption studies with complex products, including trapping devices for mass balance recovery of volatile chemicals.

We can perform dermal absorption studies with 14C radiolabeled or non-radiolabeled test substances in a variety of formulations including solids, dusts, solutions, suspensions, and vapor exposures.

Our Dermal Absorption testing capabilities include:

• Skin pharmacodynamic studies: In vitro and in vivo skin disposition studies including evaporation, deposition, percutaneous penetration, and metabolic analysis. Development of model systems for membrane transport and release studies.
• Analytical support: Radiometric analysis of 14C, 3H and 35S isotopes by liquid scintillation counting; combustion/LSC for solid matrices; chromatographic analysis using HPLC or TLC with radioisotope detection including flow-through radioisotope detection or phosphor imaging; HPLC, LC-MS, GC and GC-MS chemical analysis. Additionally, Eurofins offers analysis of metals using ICP-OES and ICP-MS.
• Formulation: Formulation of test substances including agrochemical, chemical, and personal care products.
• Radiolabeling & custom synthesis: In-house radiolabeling expertise adds the convenience of streamlined study execution and seamless project management